ClinicalTrials.gg
CompletedNCT05404542Updated Apr 2, 2024

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

A Phase 1 interventional study of Tavapadon in Renal Impairment, sponsored by Cerevel Therapeutics, LLC. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by Cerevel Therapeutics, LLC (part of AbbVie) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Renal Insufficiency by AbbVie — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · AbbVie.

Started
2022
the only one that year
Phase 1
4 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Renal Insufficiency by AbbVie, this one is the only one that started in 2022, is one of 4 in phase 1, and was the 10th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 11 studies in Renal Insufficiency by AbbVie is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Renal Insufficiency by AbbVie as a file.
02

Study summary

The primary purpose is to assess the effect of renal impairment on the PK of tavapadon following administration of a single oral dose in participants with severe renal impairment relative to age, body weight, and sex-matched participants with normal renal function.

03

Conditions studied

  • Renal Impairment

Browse trials for

Keywords

  • Healthy Volunteer
  • Severe Renal Impairment
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. of ≥18.0 to 40.0 kilograms per meter square (kg/m\^2), inclusive, and a total body weight >50 kilograms (kg) [(110 pounds (lbs)].
  2. Age that is within ±10 years of the median age for the severe renal impairment cohort. Bodyweight that is within ±15 kg of the median bodyweight for the severe renal impairment cohort.
  3. Severe renal function: estimated (eGFR) \<30 mL/min (not requiring dialysis) determined using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
  4. Stable disease, defined as no changes in disease status as documented by the most recent eGFR assessment (within at least 3 months before Screening).
  5. Stable concomitant medications for the management of individual participants medical history.

Key Exclusion Criteria:

  1. Serious risk of suicide in the opinion of the investigator.
  2. History of substance or alcohol use disorder (excluding nicotine or caffeine) within 12 months prior to signing the form (ICF).
  3. Receipt of severe acute respiratory syndrome coronavirus 2(SARS-CoV2) vaccine or booster within 7 days of planned dosing.
  4. Have recently been diagnosed with symptomatic Coronavirus Disease 2019 (COVID-19) or test positive for COVID-19 within 30 days prior to signing the ICF.
  5. Positive drug screen including tetrahydrocannabinol (THC).
  6. Positive result for (HIV) antibody, surface antigen, hepatitis B core antibody, or antibody with detectable viral ribonucleic acid (RNA) levels at Screening.
  7. Positive drug screen including THC (except with a vail prescription other than medical marijuana).
  8. Participants who have received an organ transplant or are currently waiting for an organ transplant and are listed on the national transplant list.
  9. Participants who require dialysis.
  10. Participant with nephrotic syndrome.
  11. Abnormal .
  12. Abnormal blood pressure measurement or heart rate at Screening or Check-in.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Severe Renal Impairment

    Participants with severe renal impairment will receive a single dose of tavapadon, 0.25 milligrams (mg) tablet, on Day 1.

    Drug: Tavapadon

  • Experimental
    Normal Renal Function

    Participants with normal renal function will receive a single dose of tavapadon, 0.25 mg tablet, on Day 1.

    Drug: Tavapadon

Interventions

  • Oral tablets

    Also known as: CVL-751

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Tavapadon

    Time frame: pre-dose and at multiple timepoints post-dose up to Day 7

  2. Area Under the Plasma Concentration-time Curve from Time Zero to Time t (AUC0-t) of Tavapadon

    Time frame: pre-dose and at multiple timepoints post-dose up to Day 7

  3. Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of Tavapadon

    Time frame: pre-dose and at multiple timepoints post-dose up to Day 7

Secondary outcomes

  1. Number of Participants with Adverse Events (AEs) and AEs by Severity

    Time frame: Day 1 up to Follow-up (Day 15)

  2. Number of Participants with Clinically Significant Abnormalities in Electrocardiogram (ECG) Values

    Time frame: Day 1 up to Follow-up (Day 15)

  3. Number of Participants with Clinically Significant Abnormalities in Vital Sign Values

    Time frame: Day 1 up to Follow-up (Day 15)

  4. Number of Participants with Clinically Significant Abnormalities in Laboratory Values

    Time frame: Day 1 up to Follow-up (Day 15)

  5. Number of Participants with Clinically Significant Abnormalities in Physical and Neurological Examination Results

    Time frame: Day 1 up to Follow-up (Day 15)

  6. Number of Participants with Change in Columbia Suicide Severity Rating Scale (C-SSRS) Score

    Time frame: Day 1 up to Follow-up (Day 15)

07

Study locations

3 sites
  • Jacksonville, Florida
    Jacksonville, Florida 32216, United States
  • Miami, Florida
    Miami, Florida 33147, United States
  • Tampa, Florida
    Tampa, Florida 33603, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Aug 2023, 15 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 15 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2022
First posted
Jun 3, 2022
StartActual
May 10, 2022
Primary completionActual
Aug 14, 2023
CompletionActual
Aug 14, 2023
Last update
Apr 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05404542
Responsible party
Sponsor
First posted
Jun 3, 2022
Start date
May 10, 2022
Primary completion
Aug 14, 2023
Completion
Aug 14, 2023
Last update
Apr 2, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tavapadon

Start the discussion